StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for OCGN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $1.39 | $1.34 | -3.60% | 6.6M |
| 05-19 | $1.33 | $1.30 | -2.18% | 5.6M |
| 05-20 | $1.30 | $1.36 | +4.62% | 4.0M |
| 05-21 | $1.34 | $1.35 | +0.75% | 4.1M |
| 05-22 | $1.35 | $1.34 | -0.74% | 3.9M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.53M | $4.41M | $4.61M | $2.85M |
Operating Income | $-17.84M | $-62.92M | $-45.92M | $-28.30M |
Net Income | $-19.18M | $-67.85M | $-50.14M | $-14.74M |
EPS (Diluted) | $-0.06 | Not available | Not available | Not available |
Total Assets | $56.91M | $43.52M | $57.60M | $53.59M |
Total Liabilities | $51.10M | $55.68M | $54.06M | $50.54M |
Cash & Equivalents | $31.90M | $18.89M | $32.88M | $27.32M |
Free Cash Flow OCF − CapEx | $-21.80M | $-57.15M | $-43.15M | $-30.15M |
Shares Outstanding | 338.32M | 312.38M | 312.32M | 292.19M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.